Últimas noticias sobre Danaher (NYSE:DHR) Bolsa

DANAHER CORP

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Long Ideas

News

Markets

Media

Trading Ideas

ATEN

FSLY

IESC

Jim Cramer analiza el rendimiento de varias acciones estadounidenses y comparte sus recomendaciones clave. ¿Cuáles destacan y cuáles evitar?

Cramer respalda NextEra Energy (NEE) y descarta otras acciones: ¿cuáles tienen más potencial?

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended staying away from Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>). &#8220;I'm worried. There's a lot of companies coming for Workday, and I don't <a href="https://www.benzinga.com/quote/WDAY">like that,&#8221; he added</a>.
Supporting his view, Workday, on May 22, issued second-quarter sales guidance below estimates.
Cramer said although Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) doesn't make any money, but it's a very good spec.
The recent amended Schedule 13G filing with the SEC revealed that AI hyperscaler CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) has divested its entire stake in Applied Digital.
AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) is straight up, Cramer said. &#8220;We've got to ring the register a little bit.&#8221;
As per the recent news, AST SpaceMobile, on June 25, announced a series of transactions that will result in the company issuing approximately 1.04 million incremental shares to the underlying shares of its 2032 convertible notes.
When asked about DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>), he said, &#8220;I'm going to go with the flow and tell you it's time to sell.&#8221;
On the earnings front, DocuSign, on June 5, reported quarterly earnings of 90 cents per share, which beat the analyst consensus estimate of 81 cents. Quarterly revenue came in at $763.7 million, beating the Street estimate of $748.13 million.
&#8220;I am horrified about what's happening at Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>),&#8221; Cramer said. &#8220;This stock has been such a disappointment for me.&#8221;
Danaher, meanwhile, will webcast its quarterly earnings conference call for the second quarter on Tuesday, July 22.
Cramer said SM Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>) is doing not well and recommended buying Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) in case of going with oil.
Supporting his view, Raymond James analyst John Freeman, on June 24, downgraded SM Energy from Outperform to Underperform.
Price Action:
<ul class="wp-block-list">
<li>Applied Digital shares fell 4.8% to settle at $9.82 on Wednesday.</li>
<li>AST SpaceMobile shares dipped 6.1% to close at $49.97.</li>
<li>Docusign slipped 0.8% to settle at $75.01 on Wednesday.</li>
<li>SM Energy shares fell 1.4% to close at24.68.</li>
<li>Workday shares fell 2.4% to close at $233.46.</li>
<li>Danaher shares gained 1.8% to settle at $201.00.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a></li>
</ul>
Image: Shutterstock

APLD

ASTS

CRWV

CTRA

DOCU

WDAY

Jim Cramer 'Worried' About Workday, Calls Applied Digital 'A Good Spec'

Across the recent three months, 11 analysts have shared their insights on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $233.73, with a high estimate of $260.00 and a low estimate of $205.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.62%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750798861_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Danaher's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$231.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Danaher. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Danaher compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Danaher's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Danaher's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Danaher analyst ratings.</a>
<h2>About Danaher</h2>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Understanding the Numbers: Danaher's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Challenges: Danaher's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -0.95%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Danaher's net margin excels beyond industry benchmarks, reaching 16.62%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Danaher's ROE excels beyond industry benchmarks, reaching 1.9%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.22%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.32.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Danaher Through The Eyes Of 11 Analysts

Barclays analyst Luke Sergott maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Overweight and raises the price target from $215 to $225.

Price Target

Barclays Maintains Overweight on Danaher, Raises Price Target to $225

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 2.59% on an annualized basis producing an average annual return of 13.67%. Currently, Danaher has a market capitalization of $143.13 billion. 
Buying $1000 In DHR: If an investor had bought $1000 of DHR stock 10 years ago, it would be worth $3,607.97 today based on a price of $200.00 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749681018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Danaher 10 Years Ago Would Be Worth Today

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has fallen 4.1% since its last report. The company recently reported that it has 7.45 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.81 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748872832_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 7.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Danaher?

SCIEX And Evosep Sign Reseller Agreement To Expand Access To Standardized High-Throughput Proteomics For Pharma And Biotech

<ul>
<li>Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics</li>
<li>This partnership aims to create a framework for rapid diagnostics research, development and commercialization</li>
<li>Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities</li>
</ul>
WASHINGTON, May 29, 2025 /PRNewswire/ --&nbsp;Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) ("Danaher"), a global science and technology innovator, announced today the launch of a partnership with AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) to develop and commercialize novel diagnostic tools and tests intended to help clinicians better determine which patients would most benefit from precision medicine treatments.
This partnership will utilize the newly opened Danaher Centers for Enabling Precision Medicine to support a more streamlined, end-to-end development process. The first product intended to be developed through this partnership will leverage technologies from Leica Biosystems, one of Danaher's subsidiaries. The initial focus will be on digital and computational pathology products and AI-assisted algorithms, to help clinicians better diagnose patients by identifying those who are most likely to benefit from targeted therapies.

Danaher Partners With AstraZeneca To Scale Precision Medicine, Including Developing Next Generation Of AI-Powered Diagnostics

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 1.68% on an annualized basis producing an average annual return of 12.54%. Currently, Danaher has a market capitalization of $135.98 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $325.45 today based on a price of $190.00 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748440821_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$59.00</td>
<td>$69.2K</td>
<td>2.4K</td>
<td>4.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$71.00</td>
<td>$39.1K</td>
<td>2.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$200.00</td>
<td>$102.9K</td>
<td>4.0K</td>
<td>920</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$280.00</td>
<td>$99.0K</td>
<td>1</td>
<td>650</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.00</td>
<td>$32.5K</td>
<td>3.5K</td>
<td>279</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$65.00</td>
<td>$38.1K</td>
<td>6.6K</td>
<td>264</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$190.00</td>
<td>$66.9K</td>
<td>25</td>
<td>42</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$36.00</td>
<td>$27.4K</td>
<td>266</td>
<td>38</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 7 day(s) on May 30, 2025. This event was a transfer of 752 contract(s) at a $59.00 strike. This particular put needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $69.2K, with a price of $92.0 per contract. There were 2468 open contracts at this strike prior to today, and today 4643 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bearish sentiment. It expires in 7 day(s) on May 30, 2025. Parties traded 1000 contract(s) at a $71.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $39.0 per contract. There were 2294 open contracts at this strike prior to today, and today 4086 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 238 day(s) on January 16, 2026. Parties traded 96 contract(s) at a $200.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $102.9K, with a price of $1075.0 per contract. There were 4074 open contracts at this strike prior to today, and today 920 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a put option sweep that happens to be bullish, expiring in 210 day(s) on December 19, 2025. This event was a transfer of 150 contract(s) at a $280.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $99.0K, with a price of $660.0 per contract. There were 1 open contracts at this strike prior to today, and today 650 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with bearish sentiment. It expires in 602 day(s) on January 15, 2027. Parties traded 250 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $32.5K, with a price of $130.0 per contract. There were 3518 open contracts at this strike prior to today, and today 279 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option sweep with bearish sentiment. It expires in 56 day(s) on July 18, 2025. Parties traded 53 contract(s) at a $65.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $720.0 per contract. There were 6682 open contracts at this strike prior to today, and today 264 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a put option sweep that happens to be bearish, expiring in 210 day(s) on December 19, 2025. This event was a transfer of 34 contract(s) at a $190.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $66.9K, with a price of $1970.0 per contract. There were 25 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 7 day(s) on May 30, 2025. Parties traded 15 contract(s) at a $36.00 strike. The total cost received by the writing party (or parties) was $27.4K, with a price of $1830.0 per contract. There were 266 open contracts at this strike prior to today, and today 38 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

RXRX

8 Health Care Stocks With Whale Alerts In Today's Session

High-rolling investors have positioned themselves bearish on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in DHR often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for Danaher. This is not a typical pattern.
The sentiment among these major traders is split, with 30% bullish and 69% bearish. Among all the options we identified, there was one put, amounting to $32,010, and 12 calls, totaling $1,546,396.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $192.5 to $200.0 for Danaher during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Danaher's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale trades within a strike price range from $192.5 to $200.0 in the last 30 days. 
<h3>Danaher Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747850637_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.3</td>
<td>$10.8</td>
<td>$10.8</td>
<td>$200.00</td>
<td>$540.0K</td>
<td>2.7K</td>
<td>1.5K</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.4</td>
<td>$10.8</td>
<td>$10.8</td>
<td>$200.00</td>
<td>$132.8K</td>
<td>2.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.3</td>
<td>$11.1</td>
<td>$11.3</td>
<td>$200.00</td>
<td>$131.0K</td>
<td>2.7K</td>
<td>183</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.7</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$200.00</td>
<td>$126.5K</td>
<td>2.7K</td>
<td>453</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.4</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$200.00</td>
<td>$115.5K</td>
<td>2.7K</td>
<td>605</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,974,010, the price of DHR is down by -1.03%, reaching $195.74.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>What The Experts Say On Danaher</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $243.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Danaher with a target price of $225. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Danaher, targeting a price of $260. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $250. 
&#x2A; In a cautious move, an analyst from Guggenheim downgraded its rating to Buy, setting a price target of $250. 
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on Danaher, which currently sits at a price target of $230. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on DHR Options

Looking into the current session, Danaher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) shares are trading at $197.77, after a 0.69% spike. Moreover, over the past month, the stock increased by 2.97%, but in the past year, decreased by 25.98%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747778422_0.png" alt="Past Year Chart" />

<h3>A Look at Danaher P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Danaher has a lower P/E than the aggregate P/E of 44.52 of the Life Sciences Tools &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747778422_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Danaher

<ul>
<li>N of 1 therapy uniquely developed, on demand, for infant with life-threatening rare metabolic disorder in six months</li>
<li>Results published in The New England Journal of Medicine and showcased at American Society of Gene &amp; Cell Therapy Annual Meeting</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aldevron.com&amp;esheet=54255056&amp;newsitemid=20250514568719&amp;lan=en-US&amp;anchor=Aldevron&amp;index=1&amp;md5=f817bb3d6d74ace1490fe4a80bca7115">Aldevron</a>, a global leader in the production of DNA, RNA and protein, together with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.idtdna.com&amp;esheet=54255056&amp;newsitemid=20250514568719&amp;lan=en-US&amp;anchor=Integrated+DNA+Technologies&amp;index=2&amp;md5=3ebfea33eaf0cf1493d0e4f15900af7e">Integrated DNA Technologies</a> (IDT), a global leader in genomics solutions, announced the successful manufacture of the world's first personalized CRISPR gene editing drug product to treat an infant with urea cycle disorder (UCD). With no current cure for UCDs, the Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania (Penn) engaged Aldevron and IDT, both part of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.danaher.com&amp;esheet=54255056&amp;newsitemid=20250514568719&amp;lan=en-US&amp;anchor=Danaher+Corporation&amp;index=3&amp;md5=16d1e6e69c20a6d0ce98005bd100f544">Danaher Corporation</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) to manufacture a novel mRNA-based personalized CRISPR therapy in six months—three times faster than the standard timeline for gene editing drug products.

Aldevron And Integrated DNA Technologies Manufacture World's First mRNA-Based Personalized CRISPR Gene Editing Drug Product To Treat Infant With Urea Cycle Disorder

Making a noteworthy insider sell on May 14, Steven M Rales, Chairman at Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), is reported in the latest SEC filing.
What Happened: Rales's decision to sell 1,250,000 shares of Danaher was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000313616/000095017025071618//Archives/edgar/data/313616/000095017025071618/0000950170-25-071618-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $245,919,390.
In the Thursday's morning session, Danaher's shares are currently trading at $187.0, experiencing a down of 0.44%.
<h3>Unveiling the Story Behind Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Danaher's Financial Performance</h3>
Negative Revenue Trend: Examining Danaher's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -0.95% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 61.16%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Danaher's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.33.
</li>
</ul>
Debt Management: Danaher's debt-to-equity ratio is below the industry average. With a ratio of 0.32, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 36.4 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 5.76 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 20.84, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000313616">Check Out The Full List Of Danaher's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Steven M Rales Takes Money Off The Table, Sells $245.92M In Danaher Stock

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 2.11% on an annualized basis producing an average annual return of 12.39%. Currently, Danaher has a market capitalization of $135.78 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $323.32 today based on a price of $189.73 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746822613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

A large exercise of company stock options by Christopher Paul Riley, Executive Vice President at Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) was disclosed in a new SEC filing on May 1, as part of an insider exercise.
What Happened: Disclosed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000313616/000031361625000108//Archives/edgar/data/313616/000031361625000108/0000313616-25-000108-index.htm">U.S. Securities and Exchange Commission</a>, Riley, Executive Vice President at Danaher, executed a strategic derivative sale. This involved exercising stock options for 7,801 shares of DHR, resulting in a transaction value of $955,856.
Danaher shares are trading up 1.16% at $199.0 at the time of this writing on Friday morning. Since the current price is $199.0, this makes Riley's 7,801 shares worth $955,856.
<h3>Discovering Danaher: A Closer Look</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Key Indicators: Danaher's Financial Health</h3>
Revenue Challenges: Danaher's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -0.95%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 61.16%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Danaher's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.33.
</li>
</ul>
Debt Management: Danaher's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.32.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 38.12 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 6.03, Danaher's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 21.73, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000313616">Check Out The Full List Of Danaher's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

At Danaher, Christopher Paul Riley Chooses To Exercise Options, Resulting In $955K

<ul>
<li>Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.</li>
<li>High transgene expression and improved safety profile of Aldveron's Nanoplasmid&#x2122;&nbsp;vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx&#x2122; platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.</li>
<li>A poster summarizing the data will be presented at ISCT, May 7-10, 2025, in New Orleans.</li>
</ul>
CAMBRIDGE, Mass. and FARGO, N.D., April 29, 2025 /PRNewswire/ --&nbsp;Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced,&nbsp;a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanoplasmid&#x2122; vector technology with Kytopen's Flowfect Tx&#x2122; GMP cellular engineering platform in CRISPR-mediated engineering of primary T Cells.

Kytopen And Aldevron Announce Joint Marketing Agreement To Enhance Workflow Solutions For Cell Therapy Manufacturers

Whales with a lot of money to spend have taken a noticeably bearish stance on Danaher.
Looking at options history for Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) we detected 16 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 56% with bearish.
From the overall spotted trades, 14 are puts, for a total amount of $1,099,493 and 2, calls, for a total amount of $324,480.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $170.0 to $210.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Danaher's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale activity within a strike price range from $170.0 to $210.0 in the last 30 days. 
<h3>Danaher Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745604051_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$27.2</td>
<td>$26.3</td>
<td>$27.04</td>
<td>$170.00</td>
<td>$246.0K</td>
<td align="right">127</td>
<td align="right">92</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$16.2</td>
<td>$16.2</td>
<td>$16.2</td>
<td>$210.00</td>
<td>$105.5K</td>
<td align="right">866</td>
<td align="right">418</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$17.7</td>
<td>$16.7</td>
<td>$17.23</td>
<td>$210.00</td>
<td>$103.2K</td>
<td align="right">866</td>
<td align="right">118</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$17.5</td>
<td>$15.8</td>
<td>$16.94</td>
<td>$210.00</td>
<td>$101.6K</td>
<td align="right">866</td>
<td align="right">241</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$16.5</td>
<td>$15.8</td>
<td>$15.7</td>
<td>$210.00</td>
<td>$97.3K</td>
<td align="right">866</td>
<td align="right">539</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Danaher's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,116,247, with DHR's price up by 0.15%, positioned at $196.79.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 88 days.</li>
</ul>
<h3>What Analysts Are Saying About Danaher</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $239.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS persists with their Buy rating on Danaher, maintaining a target price of $240. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $250. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $225. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Danaher, maintaining a target price of $230. 
&#x2A; In a cautious move, an analyst from Guggenheim downgraded its rating to Buy, setting a price target of $250. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 3.44% on an annualized basis producing an average annual return of 13.45%. Currently, Danaher has a market capitalization of $140.63 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $351.30 today based on a price of $196.50 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745528418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has fallen 22.13% since its last report. The company recently reported that it has 6.03 million shares sold short, which is 0.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745521224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Danaher?

Danaher Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Non-GAAP core revenue was flat compared to the expectations of a decline by a low-single-digit percentage year-over-year&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" rel="noreferrer noopener">in the first quarter</a>.
Danaher reported second-quarter adjusted EPS of $1.88,&nbsp;down from $1.92 a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44921061/danaher-beats-q1-expectations-signals-caution-ahead-in-unusual-times" rel="noreferrer noopener">beating the consensus of $1.64</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44938778/danaher-pricing-strategy-key-to-navigating-tariff-challenges-analyst" rel="noreferrer noopener">Danaher Pricing Strategy Key To Navigating Tariff Challenges: Analyst</a>
Stifel on Tuesday wrote, &#8220;DHR&#8217;s start to the year was solid, as the company posted a beat and gave positive commentary around arguably the two most trending topics: bioprocess – where the upside case has started to materialize, and tariff impacts – which appear manageable in that they can be largely offset.&#8221;
Analyst Daniel Arias says customer demand looks strong for CDMOs and big pharma. China and smaller biotech firms are still behind, even though there&#8217;s some talk of stabilization. Overall, Stifel still sees a solid case for bioprocessing growth in 2025, possibly reaching double-digit levels.
The analyst maintains the Buy rating with a <a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener">price target of $260</a>.
DHR&#8217;s stock valuation &#8220;has been a challenge for us,&#8221; the analyst wrote. Shares have sported a meaningful premium despite key businesses not having rebounded from &#8220;the 2023/2024 slowdown in biopharma.&#8221;
Stifel says management's guidance for 2025 disappointed many investors, which has brought valuation to a more approachable level.
&#8220;We believe estimates can move higher both in 2025 and 2026,&#8221; Arias said. 
The analysts see an opportunity to own DHR ahead of sentiment and end market improvement, which can yield upside for the stock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44954335/old-dominion-earnings-shine-despite-revenue-slide" target="_blank" rel="noreferrer noopener">Old Dominion Earnings Shine Despite Revenue Slide, CEO Blames &#8216;Ongoing Softness&#8217; In Economy</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Large Cap

Guidance

Health Care

General

Analyst Sees Opportunity In Danaher Stock As Sentiment Improves

Dividends

Press Releases

Danaher Announces Quarterly Dividend

Danaher to Present at Bank of America Securities Healthcare Conference

Aldevron and Integrated DNA Technologies Manufacture World's First mRNA-based Personalized CRISPR Therapy

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement

Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

Danaher Schedules Second Quarter 2025 Earnings Conference Call

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Danaher

Noticias

Últimas noticias sobre Danaher (NYSE:DHR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL